Apimeds Pharmaceuticals Boosts IPO Size by 74% Ahead of $20 Million Offering
Apimeds Pharmaceuticals has increased its IPO deal size by 74%, aiming to raise $20 million by offering 4.5 million shares priced between $4 and $5. The company is developing a bee venom-based treatment for inflammation.